Ceritinib/crizotinib/lorlatinibDrug resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1702卷 / 1期

关键词：

D O I：

10.1007/s40278-018-46183-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：73 / 73

相关论文

共 50 条

[41] CrizotinibDevelopment of crizotinib resistance in metastatic lung cancer: case report
Reactions Weekly, 2018, 1683 (1) : 229 - 229
[42] CrizotinibDevelopment of crizotinib resistance leading to disease progression: case report
Reactions Weekly, 2016, 1621 (1) : 83 - 83
[43] CrizotinibDevelopment of crizotinib-resistance in lung adenocarcinoma: case report
Reactions Weekly, 2017, 1635 (1) : 96 - 96
[44] AntineoplasticsEGFR and KRAS mutations with acquired resistance to crizotinib: case report
Reactions Weekly, 2014, 1515 (1) : 31 - 31
[45] Crizotinib/erlotinib/osimertinibDrug resistance, acne and anorexia: case report
Reactions Weekly, 2021, 1852 (1) : 144 - 144
[46] Crizotinib/erlotinib interactionDrug resistance and various other toxicities: case report
Reactions Weekly, 2015, 1567 (1) : 74 - 74
[47] Crizotinib/osimertinibVarious toxicity followed by drug-resistance: case report
Reactions Weekly, 2021, 1860 (1) : 134 - 134
[48] CrizotinibDevelopment of resistance to crizotinib during treatment of lung cancer: case report
Reactions Weekly, 2018, 1728 (1) : 114 - 114
[49] Cisplatin/crizotinib/pemetrexedLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2022, 1894 (1) : 110 - 110
[50] Crizotinib/nedaplatin/pemetrexedLack of efficacy and development of drug resistance: case report
Reactions Weekly, 2021, 1851 (1) : 120 - 120

← 1 2 3 4 5 →